Research Papers

25 of 166 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, l…
Sandborn WJ; Lawendy N; Danese S; Su C; Loftus EV; Hart A; Dotan I; Damião AOMC; Judd DT; Guo X; Modesto I; Wang W; Panés J.
Aliment Pharmacol Ther (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.
Rubin DT; Modesto I; Vermeire S; Danese S; Ng SC; Kwok KK; Koram N; Jones TV.
Aliment Pharmacol Ther (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Review article: therapeutic aspects of bile acid signalling in the gut-liver axis.
Simbrunner B; Trauner M; Reiberger T.
Aliment Pharmacol Ther (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
Doherty J; Fennessy S; Stack R; O' Morain N; Cullen G; Ryan EJ; De Gascun C; Doherty GA.
Aliment Pharmacol Ther (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patien…
Poynard T; Paradis V; Mullaert J; Deckmyn O; Gault N; Marcault E; Manchon P; Si Mohammed N; Parfait B; Ibberson M; Gautier JF; Boitard C; Czernichow S; Larger E; Drane F; Castille JM; Peta V; Brzustowski A; Terris B; Vallet-Pichard A; Roulot D; Laouénan C; Bedossa P; Castera L; Pol S; Valla D; Quid-Nash consortium.
Aliment Pharmacol Ther (Unknown)
Published: 2021
3/6 Transparent
Registered Funding Declared
Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosi…
Ribolsi M; Frazzoni M; Marabotto E; De Carlo G; Ziola S; Maniero D; Balestrieri P; Cicala M; Savarino E.
Aliment Pharmacol Ther (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders.
Sharma A; Rao SSC; Kearns K; Orleck KD; Waldman SA.
Aliment Pharmacol Ther (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease.
Lansdorp CA; Gecse KB; Buskens CJ; Löwenberg M; Stoker J; Bemelman WA; D'Haens GRAM; van Hulst RA.
Aliment Pharmacol Ther (Unknown)
Published: 2020
3/6 Transparent
Registered Funding Declared
Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination…
Dohos D; Hanák L; Szakács Z; Kiss S; Párniczky A; Erőss B; Pázmány P; Hegyi P; Sarlós P.
Aliment Pharmacol Ther (Unknown)
Published: 2020
3/6 Transparent
Registered Funding Declared
Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
Danese S; Subramaniam K; Van Zyl J; Adsul S; Lindner D; Roth J; Vermeire S.
Aliment Pharmacol Ther (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel …
Gordon C; Chee D; Hamilton B; Heerasing NM; Hendy P; Chanchlani N; Lin S; Wesley E; Daniels IR; Silva N; Osborne M; Kennedy NA; Goodhand JR; Ahmad T.
Aliment Pharmacol Ther (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibo…
Wunsch E; Norman GL; Milkiewicz M; Krawczyk M; Bentow C; Shums Z; Mahler M; Lopens S; Reinhold D; Franke A; Schramm C; Roggenbuck D; Milkiewicz P.
Aliment Pharmacol Ther (Unknown)
Published: 2020
1/6 Transparent
Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission.
van Doorn AS; Meijer B; Frampton CMA; Barclay ML; de Boer NKH.
Aliment Pharmacol Ther (Unknown)
Published: 2020
1/6 Transparent
Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of …
Cho YK; Choi MG; Choi SC; Lee KM; Kim TO; Park SH; Moon JS; Lim YJ; Kang DH; Cheon GJ; Baik GH; Kim KO; Cho KB; Jang JS; Park JJ; Son BK; Jung HK; Kim BW; Kim SK; Lee ST; Cha JM; Kim AR; Kim EJ; Park HW; Song GS.
Aliment Pharmacol Ther (Unknown)
Published: 2020
3/6 Transparent
Registered Funding Declared
The association between markers of liver injury and clinical outcomes in patients with COVID-19 in Wuhan.
Huang H; Chen S; Li H; Zhou XL; Dai Y; Wu J; Zhang J; Shao L; Yan R; Wang M; Wang J; Tu Y; Ge M.
Aliment Pharmacol Ther (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19.
Kulkarni AV; Kumar P; Tevethia HV; Premkumar M; Arab JP; Candia R; Talukdar R; Sharma M; Qi X; Rao PN; Reddy DN.
Aliment Pharmacol Ther (Unknown)
Published: 2020
2/6 Transparent
Registered
Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients.
Ponziani FR; Del Zompo F; Nesci A; Santopaolo F; Ianiro G; Pompili M; Gasbarrini A; “Gemelli against COVID-19” group.
Aliment Pharmacol Ther (Unknown)
Published: 2020
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal imp…
Lampertico P; Berg T; Buti M; Pathil A; Petersen J; Ryder SD; Zoulim F; Botros I; Flaherty JF; Jump B; Op den Brouw ML; van Troostenburg A; Ramroth H; ReCoRd (Retrospective; Cohort; Renal; Viread) Investigators' Group.
Aliment Pharmacol Ther (Unknown)
Published: 2020
3/6 Transparent
Registered Funding Declared
Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.
Hamatani T; Fukudo S; Nakada Y; Inada H; Kazumori K; Miwa H.
Aliment Pharmacol Ther (Unknown)
Published: 2020
3/6 Transparent
Registered Funding Declared
Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
Rao SSC; Xiang X; Yan Y; Rattanakovit K; Patcharatrakul T; Parr R; Ayyala D; Sharma A.
Aliment Pharmacol Ther (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Randomised clinical trial: the effectiveness of Gaviscon Advance vs non-alginate antacid in suppression of acid pocket …
Deraman MA; Abdul Hafidz MI; Lawenko RM; Ma ZF; Wong MS; Coyle C; Lee YY.
Aliment Pharmacol Ther (Unknown)
Published: 2020
3/6 Transparent
Registered Funding Declared
Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data.
Camilleri M; Lembo A; McCallum R; Tourkodimitris S; Kemps L; Miller MB; Bertelsen K; Iacob A.
Aliment Pharmacol Ther (Unknown)
Published: 2020
2/6 Transparent
Funding Declared
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver inj…
Palmer M; Regev A; Lindor K; Avigan MI; Dimick-Santos L; Treem W; Marcinak JF; Lewis JH; Anania FA; Seekins D; Shneider BL; Chalasani N.
Aliment Pharmacol Ther (Unknown)
Published: 2019
2/6 Transparent
Funding Declared
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
Sandborn WJ; Panés J; Sands BE; Reinisch W; Su C; Lawendy N; Koram N; Fan H; Jones TV; Modesto I; Quirk D; Danese S.
Aliment Pharmacol Ther (Unknown)
Published: 2019
2/6 Transparent
Funding Declared
Development of a stratification tool to identify pancreatic intraductal papillary mucinous neoplasms at lowest risk of …
Overbeek KA; Alblas M; Gausman V; Kandel P; Schweber AB; Brooks C; Van Riet PA; Wallace MB; Gonda TA; Cahen DL; Bruno MJ.
Aliment Pharmacol Ther (Unknown)
Published: 2019
2/6 Transparent
Funding Declared